Skip to content
Biodatica
Start free

Advanced Accelerator Applications

Duarte, California

OncologyPhase III
Compare Sign in to watch

What changed

Phase II trial registered: [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake

2mo agoTrial registeredApr 30, 2026Source filing (opens the source filing in a new tab)

Momentum

74no change

Momentum 74 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

329 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Jan 8, 2020

    Gastro-enteropancreatic Neuroendocrine Tumor · ACTIVE_NOT_RECRUITING · sponsor: Advanced Accelerator Applications · Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

    ClinicalTrials.gov · NCT03972488 (opens the source filing in a new tab)

  2. Trial

    PHASE1/PHASE2 registered

    May 24, 2019

    Neoplasms · COMPLETED · sponsor: Advanced Accelerator Applications · [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake

    ClinicalTrials.gov · NCT03872778 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    May 24, 2018

    Prostatic Neoplasm · TERMINATED · sponsor: Advanced Accelerator Applications · 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer

    ClinicalTrials.gov · NCT03490838 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources